Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Drugmakers have been warned that the Trump Administration is considering linking U.S. medicine prices to lower amounts paid ...

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

The Trump administration aims to change the Medicare Drug Price Negotiation Program in a way that would delay when certain ...

Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is ...

Health officials in US President Donald Trump's administration are reportedly exploring an international reference pricing ...

A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.

Drug pricing and other pilots are typically ... Top-selling blood thinner Eliquis from Bristol Myers Squibb (BMY.N), opens new tab carries a U.S. list price of $606 for a month's supply.

Like tens of thousands of Massachusetts residents, community college professor Carolyn McGrath has been paying for medicine ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Four healthcare dividend stocks with significant upside potential and safe dividends look like outstanding investing ideas ...